Publication Name	World Journal of Transplantation
Manuscript ID	56893
Country	Argentina

Received	2020-05-18 17:46
Peer-Review Started	2020-05-18 17:47
To Make the First Decision
Return for Revision	2020-06-03 17:30
Revised	2020-06-09 10:43
Second Decision	2020-09-22 11:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-09-22 20:23
Articles in Press	2020-09-22 20:23
Publication Fee Transferred
Edit the Manuscript by Language Editor	2020-10-10 06:31
Typeset the Manuscript	2020-11-08 05:43
Publish the Manuscript Online	2020-11-23 10:54

ISSN	2220-3230 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Opinion Review
Article Title	Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
Manuscript Source	Invited Manuscript
All Author List	Federico Piñero, Marcos Thompson, Juan Ignacio Marín and Marcelo Silva
Funding Agency and Grant Number
Corresponding Author	Federico Piñero, MD, MSc, Academic Research, Doctor, Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Av. Presidente Perón 1500, Pilar, Buenos Aires B1629HJ, Argentina. fpinerof@cas.austral.edu.ar
Key Words	Liver transplantation; Recurrence; Systemic therapies; Hepatocellular carcinoma; ;
Core Tip	Post-transplant hepatocellular carcinoma recurrence is a significant negative predictor of survival. There is no consensus in the treatment of recurrence. If possible, resection should be attempted. The use of systemic chemotherapy after transplant is limited to small retrospective cohort studies. Immunotherapy with checkpoint inhibitors in the post-transplant setting is challenging due to the potentially increased risk of allograft rejection. This opinion review illustrates a late post-transplant hepatocellular carcinoma recurrence treated with lenvatinib, with good tolerance and overall survival after lung and adrenal metastasis resections in a patient previously intolerant to sorafenib.
Publish Date	2020-11-23 10:54
Citation	Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306
URL	https://www.wjgnet.com/2220-3230/full/v10/i11/297.htm
DOI	https://dx.doi.org/10.5500/wjt.v10.i11.297

Full Article (PDF)	WJT-10-297.pdf
Full Article (Word)	WJT-10-297.docx
Manuscript File	56893-Review-Webster J.docx
Answering Reviewers	56893-Answering reviewers.pdf
Audio Core Tip	56893-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	56893-Conflict-of-interest statement.pdf
Copyright License Agreement	56893-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	56893-Language certificate.pdf
Peer-review Report	56893-Peer-review(s).pdf
Scientific Misconduct Check	56893-Scientific misconduct check.pdf
Scientific Editor Work List	56893-Scientific editor work list.pdf